Phase 2 trial of ABV-1703
Latest Information Update: 21 Nov 2024
At a glance
- Drugs BLI 1401 (Primary)
- Indications Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 14 Nov 2024 According to a ABVC BioPharma media release, the United States Food & Drug Administration (US FDA) has approved IND.
- 06 Mar 2023 New trial record
- 28 Feb 2023 According to a ABVC BioPharma media release, the company intends to submit IND to the Taiwan FDA after commencing clinical trials in the United States.